Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by Mount Sinai School of Medicine
Sponsor:
Collaborators:
Myeloproliferative Disorders-Research Consortium
Roche Pharma AG
QIAGEN Marseille
Information provided by (Responsible Party):
Ronald Hoffman, Mount Sinai School of Medicine
ClinicalTrials.gov Identifier:
NCT01259817
First received: December 6, 2010
Last updated: March 5, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2018
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)